Category: Bavarian Nordic

  • Monkeypox cases are rising. Should we be worried?

    The World Health Organization has said the current outbreak of monkeypox is the largest ever recorded outside sub-Saharan Africa, with cases rising above the 100-mark a few days ago and the UK top of the table with 56 as of yesterday. Top of the list of concerns is how the virus – which does not […]

  • J&J ducks out of Bavarian Nordic vaccine partnerships

    Johnson & Johnson has halved the size of its collaboration with Bavarian Nordic on vaccine development, jettisoning its stake in shots targeting human papillomavirus (HPV) and hepatitis B virus (HBV). J&J’s Janssen pharmaceuticals division said it will continue to work with the Danish biotech on vaccines targeting HIV and Ebola, but is prioritising its work […]

  • Trailing its RSV vaccine rivals, Bavarian Nordic cuts China deal

    Bavarian Nordic has licensed rights to its respiratory syncytial virus (RSV) vaccine in China and certain other Asian markets to Shanghai’s Nuance Pharma in a $225 million deal. The agreement, which also covers South Korea, Taiwan and certain markets in Southeast Asia, will see Nuance take the lead on a phase 3 trial of the […]